Aristotle University Of Thessaloniki (AUTH)
Μελέτη της επίδρασης της σπιρονολακτόνης στη έκφραση γονιδίων που σχετίζονται με τη μυοκαρδιακή ίνωση σε υπερτασικούς επιίμυες
Abstract
dc:descriptionΑldosterone was found to exert detrimental effects on cardiac structure (cardiac hypertrophy and fibrosis) and function (promotion of ventricular remodeling) both in heart failure and pressure overload conditions, whereas the blockade of its receptor has shown impressive benefits both in clinical and laboratory level. The mechanisms by which the blockade of mineralocorticoid receptor – and specifically spironolactone - reduces cardiac fibrosis include the downregulation of mRNA expression of angiotensinogen converting enzyme, the reduction of aldosterone - induced collagen production by cardiac fibroblasts and the prevention of perivascular fibrosis and oxidative stress in the coronary circulation and myocardium in general. The aim of the present study was to investigate the effect of mineralocorticoid receptor blockade by spironolactone on the expression of genes related, directly or indirectly, to cardiac fibrosis - and more specifically ΤGF-β1, ΤΝF-α and MR genes. For this purpose, 12 young male SHR rats at the age of 14 weeks and weighting 250-300 gr. were used, divided in two groups of six, one of which received spironolactone in drinking water for a month at the small dose of 20 mg/kgr body weight per day and six Wistar rats of the same sex, age and weight which served as the normotensive control group. At the end of four weeks all animals were sacrificed and the hearts were dissected. One heart from each group underwent histological examination and the rest were refrigerated in liquid nitrogen. In due time the hearts were defrosted and the study of the expression of the aforementioned genes in the myocardium, using the Polymerase Chain Reaction (PCR) method, followed. The present study showed a possible reduction of the expression of the proinflammatory cytokine TNF-α in the myocardium of young hypertensive rats under spironolactone treatment, already from the very early stages of the natural course of their disease, indicating a possible additional mechanism of action of spironolactone in the context of heart failure therapy and/or its prevention.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Stylianakis, George
- Στυλιανάκης, Γεώργιος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19542